Clinical trial
A Study of Actonel for the Prevention of Bone Loss
NCT00452439 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00452439 |
|---|---|
| Title | A Study of Actonel for the Prevention of Bone Loss |
| Official title | A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Actonel (Risedronate), Calcium, Vitamin D |
| Enrollment | 72 |
| Start date | Feb 1, 2004 |
| Primary completion | Aug 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | Mar 27, 2007 |
| Last update posted | Dec 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: